Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
Details : Imuldosa (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.
Brand Name : Imuldosa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 11, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Details : DMB-3115 (ustekinumab) is a proposed biosimilar to Stelara being used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Brand Name : DMB-3115
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 17, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
Details : DMB-3115 (ustekinumab) and Stelara demonstrated therapeutic equivalence when looking at percent change from baseline in PASI (Psoriasis Area and Severity Index) at Week 8 and Week 12.
Brand Name : DMB-3115
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Polifarma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
Details : According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.
Brand Name : DA-3880
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Polifarma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : DA-1241
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : NeuroBo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement, NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 (a novel GPR119 agonist) and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and ty...
Brand Name : DA-1241
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : DA-1241
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : NeuroBo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : DA-1241
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Recipient : NeuroBo Pharmaceuticals
Deal Size : $37.0 million
Deal Type : Licensing Agreement
Details : DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.
Brand Name : DA-1241
Molecule Type : Small molecule
Upfront Cash : $22.0 million
September 15, 2022
Lead Product(s) : DA-1241
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Recipient : NeuroBo Pharmaceuticals
Deal Size : $37.0 million
Deal Type : Licensing Agreement
Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration
Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : STP0404
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022
Details : STP0404 also demonstrated consistent pharmacokinetics at various dose levels showing drug exposure increased less-proportionally with dose, and presented an elimination half-life can support once daily dosing regimen.
Brand Name : STP0404
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Lead Product(s) : STP0404
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
